Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany Cuts Pharma Rebate Level While Keeping Price Freeze

This article was originally published in The Pink Sheet Daily

Executive Summary

German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.

You may also be interested in...

No Thaw In Sight: German Bill Extends Price Freeze To 2022

Drug price freeze introduced in 2010 would remain to 2022, under draft legislation to revise AMNOG reimbursement system. It introduces some limits on the year of free pricing that companies enjoy after launch.

German Drug Price Freeze Confirmed For Four Years In Latest Reforms

Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.

Germany’s Grand Coalition Offers Pharma Little Certainty, Except For Continued Discounts

Germany’s new grand coalition government includes a health minister with no background in health care.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts